[Form 4] Damora Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Damora Therapeutics, Inc. General Counsel Winslow Garrett reported routine equity compensation activity involving restricted stock units (RSUs) and a small share sale tied to taxes. On July 3, 2026, 680 RSUs were settled into 680 shares of common stock at a stated price of $0.00 per share as part of their scheduled vesting from a January 3, 2024 award. On the same date, 640 RSUs from this award remained outstanding. On July 6, 2026, 245 shares of common stock were sold at $29.98 per share to cover tax obligations in connection with the RSU vesting under the company’s 2020 Equity Incentive Plan, which the filing describes as a mandated, non-discretionary sale. Following these transactions, Garrett holds 2,289 shares of Damora Therapeutics common stock directly.

Insights

Equity compensation analyst

Routine RSU vesting with a small tax-driven sale; limited signal.

The filing shows 680 restricted stock units converting into common shares on July 3, 2026, from a January 3, 2024 award, with 640 RSUs remaining. This is standard equity compensation vesting for the General Counsel of Damora Therapeutics.

On July 6, 2026, 245 shares were sold at $29.98 per share. A footnote explains the shares were sold to cover tax obligations under the 2020 Equity Incentive Plan and were not a discretionary trade, which materially weakens any trading signal.

After these transactions, the insider directly holds 2,289 common shares. The net change of 245 shares sold versus 680 acquired is small, and with no remaining derivatives disclosed, this looks like routine administration of equity awards rather than a thesis-changing insider move.

Insider Trade Summary

Net Seller: 245 shares ($7,345)

Net Sell 3 txns

Insider Winslow Garrett

Role General Counsel

Sold 245 shs ($7K)

Type	Security	Shares	Price	Value
Sale	Common Stock	245	$29.98	$7K
Exercise	Restricted Stock Units	680	$0.00	--
Exercise	Common Stock	680	$0.00	--

Holdings After Transaction: Common Stock — 2,289 shares (Direct, null); Restricted Stock Units — 640 shares (Direct, null)

Footnotes (1)

1. Each restricted stock unit ("RSU") represents the right to receive, at settlement, one share of common stock of the Issuer. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date. Shares sold to cover tax obligations in connection with the vesting of the RSUs listed in Table II. This sale is mandated by the Issuer's election under its 2020 Equity Incentive Plan and does not represent a discretionary trade by the Reporting Person. This award was granted on January 3, 2024. One-third of the RSUs subject to the award vested on January 3, 2025 and one-sixth of the RSUs subject to the award award will vest ratably every six months thereafter, assuming continued employment through the applicable vesting date.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/07/2026 - 08:01 PM Accepted by SEC EDGAR 07/07/2026 - 08:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Winslow Garrett

(Last) (First) (Middle)

C/O DAMORA THERAPEUTICS, INC.

221 CRESCENT STREET, BLDG 23, STE 105

(Street)

WALTHAM MASSACHUSETTS 02453

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Damora Therapeutics, Inc. [ DMRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/03/2026		M		680	A	(1)	2,534	D
Common Stock	07/06/2026		S(2)		245	D	$29.98	2,289	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	07/03/2026		M			680	(3)	(3)	Common Stock	680	$0	640	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents the right to receive, at settlement, one share of common stock of the Issuer. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date.

2. Shares sold to cover tax obligations in connection with the vesting of the RSUs listed in Table II. This sale is mandated by the Issuer's election under its 2020 Equity Incentive Plan and does not represent a discretionary trade by the Reporting Person.

3. This award was granted on January 3, 2024. One-third of the RSUs subject to the award vested on January 3, 2025 and one-sixth of the RSUs subject to the award award will vest ratably every six months thereafter, assuming continued employment through the applicable vesting date.

	/s/ Garrett Winslow	07/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)